LV10199B - Pharmaceutical preparation of unglycosylated protein and method of preparation thereof - Google Patents

Pharmaceutical preparation of unglycosylated protein and method of preparation thereof Download PDF

Info

Publication number
LV10199B
LV10199B LVP-93-463A LV930463A LV10199B LV 10199 B LV10199 B LV 10199B LV 930463 A LV930463 A LV 930463A LV 10199 B LV10199 B LV 10199B
Authority
LV
Latvia
Prior art keywords
acid
citrate
hcl
pharmaceutical
mmol
Prior art date
Application number
LVP-93-463A
Other languages
English (en)
Latvian (lv)
Other versions
LV10199A (lv
Inventor
Ulrich Kohnert
Rainer Rudolph
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of LV10199A publication Critical patent/LV10199A/xx
Publication of LV10199B publication Critical patent/LV10199B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
LVP-93-463A 1989-12-20 1993-06-02 Pharmaceutical preparation of unglycosylated protein and method of preparation thereof LV10199B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3942143A DE3942143A1 (de) 1989-12-20 1989-12-20 T-pa pro stabilisierung
PCT/EP1990/002251 WO1991008766A1 (fr) 1989-12-20 1990-12-19 STABILISATION DE t-PA pro

Publications (2)

Publication Number Publication Date
LV10199A LV10199A (lv) 1994-10-20
LV10199B true LV10199B (en) 1995-04-20

Family

ID=6395926

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-463A LV10199B (en) 1989-12-20 1993-06-02 Pharmaceutical preparation of unglycosylated protein and method of preparation thereof

Country Status (13)

Country Link
US (1) US5352453A (fr)
EP (1) EP0458939B1 (fr)
JP (1) JPH0657661B2 (fr)
KR (1) KR920700684A (fr)
AT (1) ATE103178T1 (fr)
AU (1) AU633684B2 (fr)
CA (1) CA2046929C (fr)
DE (2) DE3942143A1 (fr)
FI (1) FI96000C (fr)
HU (2) HU208637B (fr)
LV (1) LV10199B (fr)
NO (1) NO305583B1 (fr)
WO (1) WO1991008766A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
JPH06506459A (ja) * 1991-04-16 1994-07-21 ロシュ ダイアグノスティックス ゲーエムベーハー プラスミノーゲン活性化剤を含有する多重ボーラス投与用医薬パッケージユニット
EP0639202B1 (fr) * 1992-04-30 1998-11-25 Cor Therapeutics, Inc. Compositions stables a base de polypeptides
US6001480A (en) * 1993-06-11 1999-12-14 Zexel Corporation Amorphous hard carbon film and mechanical parts coated therewith
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
JPH0678241B2 (ja) * 1986-04-02 1994-10-05 エーザイ株式会社 ｔＰＡ医薬組成物
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
AU4187389A (en) * 1988-08-02 1990-03-05 Invitron Corporation Method for preparing tpa compositions
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
JPH0813750B2 (ja) * 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤

Also Published As

Publication number Publication date
NO913118L (no) 1991-08-09
EP0458939A1 (fr) 1991-12-04
FI96000B (fi) 1996-01-15
ATE103178T1 (de) 1994-04-15
NO305583B1 (no) 1999-06-28
FI96000C (fi) 1996-04-25
JPH03505465A (ja) 1991-11-28
US5352453A (en) 1994-10-04
AU7037591A (en) 1991-07-18
NO913118D0 (no) 1991-08-09
HU912742D0 (en) 1992-01-28
HUT59610A (en) 1992-06-29
EP0458939B1 (fr) 1994-03-23
LV10199A (lv) 1994-10-20
CA2046929A1 (fr) 1991-06-21
DE3942143A1 (de) 1991-06-27
JPH0657661B2 (ja) 1994-08-03
FI913909A0 (fi) 1991-08-19
DE59005128D1 (de) 1994-04-28
AU633684B2 (en) 1993-02-04
KR920700684A (ko) 1992-08-10
WO1991008766A1 (fr) 1991-06-27
CA2046929C (fr) 1997-01-14
HU208637B (en) 1993-12-28

Similar Documents

Publication Publication Date Title
Chen et al. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1, 1′-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis
Vince et al. Glyoxalase inhibitors. A possible approach to anticancer agents
LaNoue et al. Kinetic control of mitochondrial ATP synthesis
Engstrom et al. The nature of Ca++ binding by kidney mitochondria
Seraydarian et al. Adriamycin: effect on mammalian cardiac cells in culture I. Cell population and energy metabolism
Santelli et al. In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice
WEISSLER et al. Effect of insulin on the performance and metabolism of the anoxic isolated perfused rat heart
Friedman The effect of 5-azacytidine on E. coli DNA methylase
Eda et al. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′‐deoxy‐5‐fluorouridine
US5585363A (en) Circumvention of human tumor drug resistance
Perry et al. Regulation of ornithine decarboxylase in cultured mouse mammary gland by the osmolarity in the cellular environment
Ozols et al. Phase II Trial of 5-FU Administered Ip to Patients With Refractory Ovarian
LV10199B (en) Pharmaceutical preparation of unglycosylated protein and method of preparation thereof
Cho-Chung et al. Arrest of mammary tumor growth invivo by L-arginine: Stimulation of NAD-dependent activation of adenylate cyclase
Lauter et al. Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans
FI95999C (fi) K2P-prostabilointi
Martin et al. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue
JPH0660107B2 (ja) 凝血塊を溶解するためのグリコシル化されたタンパク質の製薬学的調剤およびその製造法
Noll et al. Mitochondrial ATP-synthase activity in cardiomyocytes after aerobic-anaerobic metabolic transition
EP0461225B1 (fr) Circonvention de la resistance humaine aux medicaments de la tumeur
Hirata et al. Membrane orientation and active transport of proline
Ajani et al. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma
Dietrich et al. A comparison of the affinity of pyridoxal phosphate and deoxypyridoxine phosphate for apo-cysteine desulfhydrase
Pierson et al. Depletion of extracellular cysteine with hydroxocobalamin and ascorbate in experimental murine cancer chemotherapy
Baglioni et al. The use of phosphorylated sugars to support protein synthesis with some mammalian cell extracts